Drug profile · INN
encorafenib
BRAFTOVI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
encorafenib (BRAFTOVI) is an FDA-listed pharmaceutical active ingredient. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN encorafenib
Brand BRAFTOVI
Route ORAL
Formulation CAPSULE
ATC code L01EC03
Originator Pierre Fabre Australia Pty Ltd
Frequently asked questions
What is encorafenib?
encorafenib (BRAFTOVI) is an FDA-listed pharmaceutical active ingredient. Associated with Pierre Fabre Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for encorafenib?
BRAFTOVI is a marketed brand name for encorafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of encorafenib?
encorafenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.